Low-dose Lenalidomide for Non-severe COVID-19 Treatment Trial

NCT04361643 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

120

Enrollment

OTHER

Sponsor class

Conditions

COVID-19

Interventions

DRUG: Lenalidomide as a 5 mg capsule PO daily, days 1, 3, and 5.
DRUG: Placebo

Sponsor

Hospital Universitario Getafe